Dr. Andreas Herrmann has 25 years of experience in biopharmaceutical and biosimilar development.

As a serial entrepreneur, Dr. Herrmann successfully (co-)founded several biotech companies. From 2013–2016, he built up Alvotech, a leading biosimilars company based in Iceland with a four product pipeline and 14,000 sqm manufacturing plant and made two successful acquisitions and other strategic initiatives.

From 2003-2013, he (co-)founded seven different biotech companies including Celonic (contract manufacturing organization), Baliopharm (innovator company for autoimmune diseases, oncology), Synimmune (bispecific antibodies, oncology), ICAAN (Aesthetic Navigation), Icelandic Natura (Topica), and Probiocon (Consulting). In 1996, Dr. Herrmann co-founded Cardion AG where he was heading the R&D department until 2003. He received his PhD in biochemistry in the field of neurobiology at the University of Cologne and worked as an associate professor in the department of cardiovascular physiology at the University of Düsseldorf.

Stefanie Herrmann-Zahn has about 20 years of experience in the development of biopharmaceutical compounds.

Mrs. Herrmann-Zahn gained her diploma as a chemical engineer at Krefeld in 1997. She then joined AGS, where she worked as scientist in the fields of fermentation and enzyme purification. In 1998, she joined Cardion, where she led the biopharmaceutical development department including cell culture, process development, manufacturing and quality control.

In 2003, Mrs. Herrmann-Zahn worked at Celonic GmbH as Head of Process Development in Jülich before she became Head of Production at the GMP Facility of Celonic AG in Basel. Furthermore, she was appointed as VP Project Management.

From 2014–2016, Mrs. Herrmann-Zahn was VP Project Management at Alvotech, where she was leading cross-functional teams for the development of four biosimilar products.